SHC Quote, Financials, Valuation and Earnings

Fonar has a net margin of -5.21% compared to Sotera Health's net margin of 9.23%. Sotera Health's return on equity of 5.79% beat Fonar's return on equity of 5.33%.

Sotera Health has a consensus price target of $14.50, signalling upside risk potential of 28.09%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Sotera Health has higher upside potential than Fonar, analysts believe Sotera Health is more attractive than Fonar.

Sotera Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fonar has a beta of 0.993, suggesting its less volatile than the S&P 500 by 0.67700000000001%.

Sotera Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

Sotera Health quarterly revenues are $254.5M, which are larger than Fonar quarterly revenues of $27.2M. Sotera Health's net income of -$13.3M is lower than Fonar's net income of $2.5M. Notably, Sotera Health's price-to-earnings ratio is 141.50x while Fonar's PE ratio is 11.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health is 2.91x versus 0.92x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of -5.21% compared to Sotera Health's net margin of -209.38%. Sotera Health's return on equity of 5.79% beat ProPhase Labs's return on equity of -144.22%.

Sotera Health has a consensus price target of $14.50, signalling upside risk potential of 28.09%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3533.49%. Given that ProPhase Labs has higher upside potential than Sotera Health, analysts believe ProPhase Labs is more attractive than Sotera Health.

Sotera Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.433, suggesting its less volatile than the S&P 500 by 143.298%.

Sotera Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Sotera Health quarterly revenues are $254.5M, which are larger than ProPhase Labs quarterly revenues of $1.4M. Sotera Health's net income of -$13.3M is lower than ProPhase Labs's net income of $4M. Notably, Sotera Health's price-to-earnings ratio is 141.50x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health is 2.91x versus 2.06x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific has a net margin of -5.21% compared to Sotera Health's net margin of 14.54%. Sotera Health's return on equity of 5.79% beat Thermo Fisher Scientific's return on equity of 13.49%.

Sotera Health has a consensus price target of $14.50, signalling upside risk potential of 28.09%. On the other hand Thermo Fisher Scientific has an analysts' consensus of $554.49 which suggests that it could grow by 35.81%. Given that Thermo Fisher Scientific has higher upside potential than Sotera Health, analysts believe Thermo Fisher Scientific is more attractive than Sotera Health.

Sotera Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Thermo Fisher Scientific has a beta of 0.778, suggesting its less volatile than the S&P 500 by 22.202%.

Sotera Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific offers a yield of 0.4% to investors and pays a quarterly dividend of $0.43 per share. Sotera Health pays -- of its earnings as a dividend. Thermo Fisher Scientific pays out 9.2% of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sotera Health quarterly revenues are $254.5M, which are smaller than Thermo Fisher Scientific quarterly revenues of $10.4B. Sotera Health's net income of -$13.3M is lower than Thermo Fisher Scientific's net income of $1.5B. Notably, Sotera Health's price-to-earnings ratio is 141.50x while Thermo Fisher Scientific's PE ratio is 23.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health is 2.91x versus 3.64x for Thermo Fisher Scientific. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of -5.21% compared to Sotera Health's net margin of -67.19%. Sotera Health's return on equity of 5.79% beat XWELL's return on equity of -153.74%.

Sotera Health has a consensus price target of $14.50, signalling upside risk potential of 28.09%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 644.68%. Given that XWELL has higher upside potential than Sotera Health, analysts believe XWELL is more attractive than Sotera Health.

Sotera Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison XWELL has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.658%.

Sotera Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Sotera Health quarterly revenues are $254.5M, which are larger than XWELL quarterly revenues of $7M. Sotera Health's net income of -$13.3M is lower than XWELL's net income of -$4.7M. Notably, Sotera Health's price-to-earnings ratio is 141.50x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health is 2.91x versus 0.14x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.